Results 161 to 170 of about 417,281 (310)

A Cascaded DNA Nanocircuit for Multi‐Signal‐Responsive Precision siRNA Delivery in Cancer Therapy

open access: yesAdvanced Science, EarlyView.
A cascaded dual‐AND logic DNA nanocircuit is engineered to respond to three tumor‐specific signals in a sequential manner: extracellular acidic pH, membrane‐overexpressed nucleolin (NCL), and intracellular glutathione (GSH). This programmable system selectively releases siPARP1 in glioblastoma (GBM), effectively silencing PARP1 and reversing TMZ ...
Yan Zhao   +14 more
wiley   +1 more source

Apis mellifera L., paliasa-madu, sel kanker, IC50

open access: yes, 2014
Penelitian yang telah dilakukan sebelumnya menunjukkan bahwa paliasa-madu mampu memperbaiki kerusakan sel hepatosit secara in vivo, terutama paliasa-madu yang dihasilkan oleh Apis mellifera L.
Aliyah
core  

A Unified Hierarchical Multiscale Fusion Framework for Drug–Target Affinity Prediction: From Benchmark Performance to Nanomolar Inhibitor Discovery

open access: yesAdvanced Science, EarlyView.
A multimodal fusion framework integrating sequence, atomic, and fragment representations captures drug–target interactions across multiple scales. The model delivers strong predictive performance and enables efficient virtual screening. Applied to hematopoietic progenitor kinase 1 (HPK1), it identifies structurally diverse inhibitors with nanomolar ...
Shuo Liu   +7 more
wiley   +1 more source

Repurposing FDA‐Approved Drugs to Inhibit Fungal PPTases for Broad‐Spectrum Synergy

open access: yesAdvanced Science, EarlyView.
Fungal secondary metabolites serve as crucial virulence effectors; however, the potential of their biosynthetic pathways as antifungal targets remains inadequately comprehended. Repurposed FDA‐approved drugs inhibit fungal PPTase (essential for secondary metabolism) in vivo.
Zili Song   +7 more
wiley   +1 more source

AS‐TLC‐Based High‐Throughput Screening Integrated with CuAAC Optimization Strategy Facilitates the Rapid Discovery of YTHDC1 Inhibitor

open access: yesAdvanced Science, EarlyView.
We developed Affinity Selection Thin‐Layer Chromatography (AS‐TLC) as a method for high‐throughput screening (HTS) of compound mixtures. Furthermore, we integrated activity assays with AS‐TLC and identified a YTH domain‐containing protein 1 (YTHDC1) inhibitor. Building on this hit, we applied copper(I)‐catalyzed azide–alkyne cycloaddition (CuAAC) click
Mingchen Wang   +19 more
wiley   +1 more source

The Effect of Ligand Reactivity and Carrier Mechanics on Thiol‐Mediated Cellular Uptake for miRNA Nano‐Drugs

open access: yesAdvanced Science, EarlyView.
The effect of ligand reactivity and carrier mechanics on thiol‐mediated uptake was investigated at the single‐molecule/particle level. The interaction kinetics of LA and AspA with membrane thiols were quantified; AspA is more efficient due to the higher binding affinity, greater binding stability, and more double‐disulfide binding, as well as greater ...
Zhuang Zhang   +7 more
wiley   +1 more source

Structural Basis of Shiga Toxin Neutralization by Human Antibodies Targeting Canonical Receptor‐Binding and Non‐Canonical Assembly Sites

open access: yesAdvanced Science, EarlyView.
Cryo‐electron microscopy structures reveal two distinct neutralization mechanisms of fully human monoclonal antibodies targeting the Shiga toxin 1a B subunit. RDS059 occludes the Gb3 receptor‐binding site, whereas RDS045 engages a lateral quaternary epitope to disrupt holotoxin assembly.
Jianting Ke   +10 more
wiley   +1 more source

DIXDC1 Promotes Lymphatic Metastasis and Resistance to Cuproptosis in Bladder Cancer Through Mediating DLAT

open access: yesAdvanced Science, EarlyView.
DIXDC1 drives bladder cancer progression by binding and stabilizing DLAT. This axis enhances NEK7 and CCNE2 mRNA stability to promote proliferation and lymphatic metastasis, while limiting copper‐induced DLAT oligomerization to reduce cuproptosis sensitivity, identifying DIXDC1 as a potential target linking metastasis with cuproptosis resistance ...
Hongqiong Li   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy